$11,233.41 consulting Payment -- AbbVie Inc to Dr. Scott Collins
Oncology Physician Receives $11,233 Consulting Fee from AbbVie for Jardiance-Related Services
This page provides a detailed analysis of a $11,233.41 consulting payment from AbbVie Inc to Dr. Scott Collins. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $11,233.41 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | AbbVie Inc |
| Physician | Dr. Scott Collins |
| NPI Number | 1103658316 |
| Physician Specialty | Oncology |
| Location | Lowell, MA |
| Date of Payment | 2025-04-14 |
| Related Drug/Device | Jardiance |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AbbVie Inc made a $11.2K consulting payment to Scott Collins, a Oncology specialist in Lowell, MA. The payment was associated with Jardiance. The payment of $11,233.41 to Dr. Scott Collins for consulting services is a significant amount for a single engagement. The payment is associated with Jardiance, a drug used for diabetes, which may indicate a focus on metabolic or cardiovascular conditions within oncology. The consulting fee was paid by AbbVie Inc., a major pharmaceutical company with a broad portfolio.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment may indicate your doctor is involved in advising pharmaceutical companies on treatments like Jardiance, which is typically used for diabetes. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For an Oncology specialist, a $11,233 consulting fee from a major pharma company like AbbVie for services related to a diabetes medication like Jardiance is a notable payment, potentially exceeding typical consulting arrangements for non-specialty-aligned services.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements for payments made by manufacturers of drugs, devices, or biologics to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- oncology
- consulting-fees
- abbvie
- jardiance
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $11.2K payment for?
This was a consulting payment of $11.2K from AbbVie Inc to Scott Collins, categorized as "Consulting Fee". It was associated with Jardiance. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Scott Collins accept pharmaceutical money?
Yes, Scott Collins received this $11.2K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Scott Collins's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $11.2K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Scott Collins's relationship with AbbVie Inc?
The payment date of April 14, 2025, is in the future, suggesting this record might be a pre-publication or projected data point. This $11.2K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
Dr. Collins' specialty is listed as Oncology, while Jardiance is primarily used for Type 2 Diabetes, raising questions about the specific consulting nature.
What should patients do after learning about this payment?
If you are a patient, this payment may indicate your doctor is involved in advising pharmaceutical companies on treatments like Jardiance, which is typically used for diabetes.
What else should I know about this consulting payment?
The payment was made for 'Consulting Fee' under the 'consulting' payment type, indicating a formal agreement for advisory services.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.